Citadel Advisors
ENVB icon

Citadel Advisors’s Enveric Biosciences ENVB Stock Holding History

Citadel Advisors’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$10K – 13155
2022
Q1 		$10K Sell
3
-2
-40% -$8.84K ﹤0.01% 13377
2021
Q4 		$43K Sell
5
-1
-17% -$14.1K ﹤0.01% 13325
2021
Q3 		$109K Buy
+6
New +$116K ﹤0.01% 12767

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's ENVB Position: Q2 2026 in Review

Citadel Advisors opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 13,965 shares worth $19.3K. The stake represents ﹤0.01% of the portfolio and ranks #13410 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ENVB as recently as Q3 2025.

Citadel Advisors first reported a position in ENVB in Q4 2020 and has held it in 12 quarters since. The position peaked at $179K in Q3 2021. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • Citadel Advisors held 13,965 shares of Enveric Biosciences worth $19.3K as of Q2 2026.
  • Enveric Biosciences was a new Citadel Advisors position in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13410 holding.
  • Citadel Advisors first reported a position in Enveric Biosciences in Q4 2020 and has held it in 12 quarters since.
  • Citadel Advisors's Enveric Biosciences position peaked at $179K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.